^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CodaLytic
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Codagenix
Drug class:
Immunostimulant
Related drugs:
1year
The codon-modified influenza virus CodaLytic™rescues immunostimulatory activity and anti-tumor efficacy in PD-1-refractory tumor models (AACR 2023)
Primary human tumoroids were incubated with CodaLytic +/- 10 μg/ml pembrolizumab using the 3D-Explore platform by Nilogen Oncosystems. Taken together, this and additional preclinical data confirms the emergence of CodaLytic as a potent immunostimulatory agent capable of restoring immune cell infiltration and anti-tumor efficacy when used in combination with checkpoint inhibition in PD-1 resistant models. This data supports future development of CodaLytic for immuno-virotherapy of tumor types in which checkpoint therapy is less established.
Preclinical
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CCL4 (Chemokine (C-C motif) ligand 4) • CCL2 (Chemokine (C-C motif) ligand 2)
|
Keytruda (pembrolizumab) • CodaLytic
Share via
